1 – 10 of 166
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Treatment outcomes of childhood PICALM::MLLT10 acute leukaemias
2023) In British Journal of Haematology(
- Contribution to journal › Article
-
Mark
The role of T cells and myeloid-derived suppressor cells in refractory immune thrombocytopenia
(
- Contribution to journal › Scientific review
- 2022
-
Mark
Use of dipyridamole is associated with lower risk of lymphoid neoplasms : a propensity score-matched cohort study
(
- Contribution to journal › Article
-
Mark
Idelalisib in relapsed/refractory diffuse large B-cell lymphoma : results from a Nordic Lymphoma Group phase II trial
(
- Contribution to journal › Letter
-
Mark
Outcomes of relapsed/refractory diffuse large B-cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second line—A population-based study of 736 patients
(
- Contribution to journal › Article
-
Mark
A survey on thromboprophylaxis and coagulation assessment in children and young adults with acute lymphoblastic leukaemia (ALL) in the Nordic and Baltic countries : Different practices of assessment and management
(
- Contribution to journal › Article
- 2021
-
Mark
How should we use ibrutinib in patients with mantle cell lymphoma?
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Infiltration of CD163-, PD-L1- and FoxP3-positive cells adversely affects outcome in patients with mantle cell lymphoma independent of established risk factors
(
- Contribution to journal › Article
-
Mark
Successful tyrosine kinase inhibitor discontinuation outside clinical trials — data from the population-based Swedish chronic myeloid leukaemia registry
(
- Contribution to journal › Article
-
Mark
Parental origin of monosomy 7 in acute leukaemia
2021) In British Journal of Haematology(
- Contribution to journal › Letter